维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

3篇 您的检索式：作者名="Steven L Lansman"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Predictors of adverse outcome and transient neurological dysfunction after ascending aorta/hemiarch replacement显示文摘	Marek P Ehrlich M.Arisan Ergin Jock N McCullough Steven L Lansman Jan D Galla Carol A Bodian Anil Z Apaydin Randall B Griepp	2000	The Annals of Thoracic Surgery2000，，6：	1
	2	Acute type B aortic dissection: surgical therapy显示文摘	Steven L Lansman Christian Hagl Daniel Fink Jan D Galla David Spielvogel M.Arisan Ergin Randall B Griep	2002	The Annals of Thoracic Surgery2002，，5：	1
	3	A meta-analysis of 1-year outcomes of transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis显示文摘Background Transcatheter aortic valve replacement(TAVR)for the treatment symptomatic severe aortic stenosis(AS)is indicated in patients with intermediate or higher surgical risk.Latest trials showed TAVR,and surgical aortic valve replacement(SAVR)perform similarly at 1-year for the composite outcomes of mortality,stroke and rehospitalization.We performed a comprehensive meta-analysis to compare individual outcomes at 1-year for TAVR compared to SAVR in low-risk patients.Methods Pub Med,Embase,and Cochrane central were searched for all the randomized controlled trials(RCTs)that reported 1-year comparative outcomes of TAVR and surgical aortic valve replacement(SAVR).Our conclusions are based upon the random-effects model using Der Simonian-Laird estimator.Results Data from 4 trials and 2887 randomized patients showed that TAVR had lower rates of all-cause mortality,cardiovascular mortality,and atrial fibrillation compared to SAVR at 1-year follow-up(P<0.05 for all).Also,TAVR was also associated with a significantly higher risk of permanent pacemaker implantation and moderate-severe paravalvular leak(P<0.05).Conclusions The latest randomised trial data demonstrates that in short-term,TAVR is safe and effective in reducing all-cause mortality or stroke.Longer follow-up of RCTs is needed to determine the durability of clinical benefits in TAVR over SAVR in low-risk patients.	Aaqib H Malik Syed Zaid Hasan Ahmad Joshua Goldberg Tanya Dutta Cenap Undemir Martin Cohen Wilbert S Aronow Steven L Lansman	2020	Journal of Geriatric Cardiology2020，17，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费